UY37764A - Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) - Google Patents

Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)

Info

Publication number
UY37764A
UY37764A UY0001037764A UY37764A UY37764A UY 37764 A UY37764 A UY 37764A UY 0001037764 A UY0001037764 A UY 0001037764A UY 37764 A UY37764 A UY 37764A UY 37764 A UY37764 A UY 37764A
Authority
UY
Uruguay
Prior art keywords
pgds
hematopoyética
prostaglandina
sintasa
compound
Prior art date
Application number
UY0001037764A
Other languages
English (en)
Inventor
Barry George Shearer
David Norman Deaton
Mark Andrew Youngman
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37764A publication Critical patent/UY37764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (I) en donde R1, R2, R3, R4, X, Y, y A se han definido en la presente memoria. Los compuestos de la presente invención son inhibidores de la Prostaglandina D Sintasa Hematopoyética (H-PGDS) y pueden ser útiles en el tratamiento de la distrofia muscular de Duchenne. La invención se refiere adicionalmente a composiciones farmacéuticas que comprenden un compuesto de la invención. La invención también se refiere adicionalmente a métodos de inhibición de la actividad de H-PGDS y tratamiento de trastornos asociados con la misma que utilizan un compuesto de la invención o una composición farmacéutica que comprende un compuesto de la invención
UY0001037764A 2017-06-13 2018-06-11 Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) UY37764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518779P 2017-06-13 2017-06-13
US201762522869P 2017-06-21 2017-06-21

Publications (1)

Publication Number Publication Date
UY37764A true UY37764A (es) 2019-01-02

Family

ID=62948277

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037764A UY37764A (es) 2017-06-13 2018-06-11 Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)

Country Status (9)

Country Link
US (1) US11149035B2 (es)
EP (1) EP3638672A1 (es)
JP (1) JP2020523367A (es)
CN (1) CN110753692A (es)
BR (1) BR112019026452A2 (es)
CA (1) CA3066979A1 (es)
TW (1) TW201908311A (es)
UY (1) UY37764A (es)
WO (1) WO2018229629A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011889A2 (pt) * 2017-12-13 2020-11-24 Glaxosmithkline Intellectual Property Development Limited piridinas fundidas que agem como inibidores de h-pgds
US20220009918A1 (en) * 2018-11-08 2022-01-13 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
CN109651241B (zh) * 2018-12-27 2021-02-09 上海毕得医药科技股份有限公司 一种4-溴-6-氯烟醛的合成方法
CN115667259A (zh) 2020-06-19 2023-01-31 佐藤制药株式会社 抑制h-pgds的稠环化合物
CN112430632B (zh) * 2020-11-18 2022-09-13 上海合全药物研发有限公司 2-((反式)-4-氨基环己烷基)异丙醇的制备方法
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146871A0 (en) 1999-06-02 2002-08-14 Nps Pharma Inc Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
AU2003249532A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20070589A1 (es) 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
WO2008075172A2 (en) 2006-12-19 2008-06-26 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PT2142516E (pt) 2007-03-30 2013-03-07 Sanofi Sa Compostos de hidrazida de pirimidina como inibidores de pgds
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
MY159870A (en) 2009-03-09 2017-02-15 Taiho Pharmaceutical Co Ltd Piperazine compound capable of inhibiting prostaglandin d synthase
JP2011042643A (ja) 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
US20120196854A1 (en) 2009-10-06 2012-08-02 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition comprising aromatic heterocyclic compound
JP5753176B2 (ja) 2009-10-08 2015-07-22 サノフイ Ｐｇｄｓ阻害剤としてのフェニルオキサジアゾール誘導体
JP5677325B2 (ja) * 2010-01-22 2015-02-25 大鵬薬品工業株式会社 Ｐｇｄｓ阻害作用を有するピペラジン化合物
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2013134298A1 (en) 2012-03-07 2013-09-12 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
EP2877166B1 (en) 2012-07-27 2018-02-28 Biogen MA Inc. 1-[7-(cis-4-methyl-cyclohexyloxy)-8-trifluoromethyl-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid derivatives as autotaxin (ATX) modulators for treating inflammations and autoimmune disorders
WO2014018891A1 (en) 2012-07-27 2014-01-30 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
CA2931589C (en) 2013-12-09 2022-01-04 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
WO2016116900A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
RU2018126105A (ru) * 2015-12-17 2020-01-17 Астекс Терапьютикс Лимитед Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds
WO2017146128A1 (ja) * 2016-02-26 2017-08-31 大日本住友製薬株式会社 イミダゾリルアミド誘導体
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
BR112020011889A2 (pt) * 2017-12-13 2020-11-24 Glaxosmithkline Intellectual Property Development Limited piridinas fundidas que agem como inibidores de h-pgds

Also Published As

Publication number Publication date
CN110753692A (zh) 2020-02-04
BR112019026452A2 (pt) 2020-07-14
WO2018229629A1 (en) 2018-12-20
CA3066979A1 (en) 2018-12-20
US11149035B2 (en) 2021-10-19
JP2020523367A (ja) 2020-08-06
US20200123152A1 (en) 2020-04-23
EP3638672A1 (en) 2020-04-22
TW201908311A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
BR112015022804A2 (pt) novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12018502012A1 (en) Griseofulvin compound
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
CL2021000421A1 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende.
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
EA202090750A1 (ru) Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами
MX2020007342A (es) Compuestos de sililetinilo hetarilo como inhibidores de la nitrificacion.
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo